Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.06 USD | +1.74% | -4.09% | +31.40% |
Apr. 30 | JPMorgan Starts Immunome With Overweight Rating, $24 Price Target | MT |
Apr. 25 | Immunome, Inc. Appoints Sandra M. Swain to Board of Directors | CI |
Financials (USD)
Sales 2024 * | 8M | Sales 2025 * | - | Capitalization | 843M |
---|---|---|---|---|---|
Net income 2024 * | -114M | Net income 2025 * | -144M | EV / Sales 2024 * | 105 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.03
x | P/E ratio 2025 * |
-6.25
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.56% |
1 day | +1.74% | ||
1 week | -4.09% | ||
1 month | -43.03% | ||
3 months | -15.15% | ||
6 months | +59.77% | ||
Current year | +31.40% |
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 64 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | Jan. 01 |
Director/Board Member | 70 | Nov. 06 | |
Clay Siegall
CEO | Chief Executive Officer | 64 | 23-10-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 14.06 | +1.74% | 1,541,409 |
24-04-29 | 13.82 | +0.66% | 786,933 |
24-04-26 | 13.73 | -3.72% | 967,621 |
24-04-25 | 14.26 | -0.07% | 737,149 |
24-04-24 | 14.27 | -2.66% | 555,483 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.40% | 843M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.21% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- IMNM Stock